Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Molecular cancer therapeutics - 1 Dec 2014

Panka David J, Buchbinder Elizabeth, Giobbie-Hurder Anita, Schalck Aislyn P, Montaser-Kouhsari Laleh, Sepehr Alireza, Lawrence Donald P, McDermott David F, Cohen Rachel, Carlson Alexander, Wargo Jennifer A, Merritt Ryan, Seery Virginia J, Hodi F Stephen, Gunturi Anasuya, Fredrick Dennie, Atkins Michael B, Iafrate A John, Flaherty Keith T, Mier James W, Sullivan Ryan J

Abstract excerpt

BRAF inhibitors (BRAFi) have led to clinical benefit in patients with melanoma. The development of a blood-based assay to detect and quantify BRAF levels in these patients has diagnostic, prognostic, and predictive capabilities that could guide treatment decisions. Blood BRAF(V600E) detection and quantification were performed on samples from 128 patients with stage II (19), III (67), and IV (42) melanoma. Tissue...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to Leukocytes, Mononuclear

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 25319388
DOI: 10.1158/1535-7163.MCT-14-0349
PMCID: PMC4258469

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.PMID 25319388Read ↗

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineSemantic proximity Read ↗

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating BiomarkersSemantic proximity Read ↗

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.Semantic proximity Read ↗

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Semantic proximity Read ↗

Usefulness of Monitoring Circulating Tumor Cells as a Therapeutic Biomarker in Melanoma with BRAF MutationSemantic proximity Read ↗

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.Semantic proximity Read ↗

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.Semantic proximity Read ↗

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.Semantic proximity Read ↗

Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma.Semantic proximity Read ↗

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma.Semantic proximity Read ↗

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.Semantic proximity Read ↗

Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.